-

Dexcom Invites the Diabetes Community to #seediabetes This November and Share Their Diabetes Story With Custom Continuous Glucose Monitor (CGM) Patches

  • Dexcom Warriors Henry Slade, Roxy Horner, Sheku Kanneh-Mason and Eoin Costelloe unveil their custom Dexcom continuous glucose monitor (CGM) patches to tell their ‘Diabetes Story’
  • On World Diabetes Day and throughout the month of November, people with diabetes and their support systems are banding together around the globe to help the diabetes community feel more seen and heard
  • Join the conversation with #SeeDiabetes and visit UK.SeeDiabetes.com to design your own custom patch

EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring, its global partners and Dexcom Warriors will once again help the world #SeeDiabetes and empower members of the diabetes community to express their unique journey with diabetes in an accessible way – by creating custom Dexcom CGM patches via the newly launched design site that illustrate just how unique each person’s diabetes story is.

To kick off the activities in the UK and Ireland, four of Dexcom’s local Celebrity Warriors have been busy designing their own custom Dexcom CGM patches, showcasing their personal stories to help people with diabetes feel seen and heard wherever they live—including celloist Sheku Kanneh-Mason (diagnosed aged 12), England Rugby player Henry Slade (diagnosed aged 18), fitness influencer Eoin Costelloe (diagnosed aged 19) and model Roxy Horner (diagnosed aged 30). These patches will illustrate what it means to them to #SeeDiabetes and encourage others to take part.

Henry Slade, professional Rugby player and Dexcom Warrior: “Raising awareness of diabetes has always been important to me. I had great role models growing up, especially watching my dad successfully manage his diabetes while continuing to play sport, and I’ve learned there’s nothing you can’t do. The patch I’ve designed is a testament to this, celebrating my achievements with Exeter and the impact Dexcom CGM has had on my diabetes journey.”

To get involved in the conversation and help people with diabetes feel seen and heard, Dexcom is asking those with diabetes, their family and friends to visit UK.SeeDiabetes.com to design their own custom patch, illustrating their personal Diabetes Story and sharing pictures on social media using the hashtag #SeeDiabetes. Dexcom will also be giving away patches to the first 500 designs in the UK and Ireland, while supplies last.

Ben Byrne, Country Director UK & Ireland: “We know from our Warrior community that diabetes can sometimes feel invisible, made even more apparent by a lack of understanding from those outside the diabetes community. So on World Diabetes Day, we are showcasing all of the amazing diabetes stories to help as many people feel seen and heard.”

About DexCom, Inc.

DexCom, Inc. empowers people to take real-time control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com/en-GB.

Dexcom

NASDAQ:DXCM

Release Versions

More News From Dexcom

Dexcom Further Advances Vision of Glucose Biosensing for All

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of milestones that advance its vision of making glucose biosensing more accessible. Notably, the company announced pediatric clearance for the Stelo Glucose Biosensor and the launch of its fully reimagined Stelo app experience in July for Apple iPhone and Android users in the United States.“Glucose matters for everyone and better understanding it can h...

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with a routine care control group using self-monitoring of blood glucose.1 Researchers presented these results today as an oral presentation at the 2026 Scientific Sessions of...

Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of diabetes and ushering in a new era of early stage CGM intervention and preventative care at the American Diabetes Association’s Scientific Sessions in New Orleans, June 5-8, 2026. “Dexcom has built a legacy of innovation within the diabetes space and as we look to the future, e...
Back to Newsroom